Asia Tech Wire (Sep 2) -- Bristol-Myers Squibb's Chinese arm announced Monday the official launch of its cancer treatment Abraxane in China.

Abraxane, an original product of albumin paclitaxel, is approved in China for the first-line treatment of metastatic pancreatic cancer in combination with gemcitabine.

The drug is also indicated for the treatment of metastatic breast cancer patients who have failed combination chemotherapy or who have relapsed within six months after adjuvant chemotherapy.